RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:NBOC increases their holding by 117 per cent
They have in house scientists with PHD/post doctoral/ M.Sc.etc. degrees and multi decade expertise in Biochemistry / Pharmacology/Medicinal Chemistry/liquid chromatography human metabolomics…
Add to that UQAM team including professor Richard Bliveau. Now they added external
scientists to assist with the sub analysis of the human data thus far.
Point is even excluding Dr. Rothenberg they have a bunch of scientists some hired as early as 2021 and some as late as second half of 2022 including oncology project managers . Not to mention the trial had to be approved by FDA’s own advisory scientific panel and run by experienced oncologist in various hospitals. So I don’t think all those folks and their assessments and reassessments have less value or credibility on the overall potential design/best outcome of the study than one poster on this board. Can all these folks be wrong and JMF’s contradicting messages be correct???